Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

This study is testing whether a drug called elranatamab — a type of immune therapy (bispecific antibody) that helps the immune system find and destroy multiple myeloma cells — can be used as maintenance therapy after a stem cell transplant in patients whose myeloma is still detectable by highly sensitive testing (measurable residual disease, or MRD). **You may be eligible if...** - You are 18 or older with newly diagnosed IgG or IgA multiple myeloma - You received an autologous stem cell transplant (using your own stem cells) as part of your initial treatment - Sensitive testing shows residual myeloma cells are still present after transplant (MRD positive) - Your overall health is adequate for treatment **You may NOT be eligible if...** - Your myeloma is MRD-negative after transplant (no detectable residual disease) - You have another active cancer being treated - You have significant organ damage or active serious infections Talk to your doctor to see if this trial is right for you.